GM Advisory Group Inc. grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 972.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,522 shares of the company’s stock after purchasing an additional 22,236 shares during the quarter. GM Advisory Group Inc.’s holdings in Merck & Co., Inc. were worth $1,887,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Sowa Financial Group Inc. bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $27,000. Total Clarity Wealth Management Inc. bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $27,000. Stephenson National Bank & Trust acquired a new position in Merck & Co., Inc. in the 4th quarter valued at $28,000. Pacifica Partners Inc. acquired a new position in Merck & Co., Inc. in the 4th quarter valued at $35,000. Finally, Lion Street Advisors LLC acquired a new position in Merck & Co., Inc. in the 1st quarter valued at $35,000. Institutional investors and hedge funds own 74.33% of the company’s stock.

Shares of MRK stock traded up $1.23 during trading on Wednesday, reaching $82.07. The company’s stock had a trading volume of 9,930,817 shares, compared to its average volume of 9,903,773. The business has a fifty day moving average price of $79.39 and a 200-day moving average price of $83.05. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 0.82. The company has a market cap of $204.50 billion, a price-to-earnings ratio of 20.64, a price-to-earnings-growth ratio of 2.22 and a beta of 0.50. Merck & Co., Inc. has a one year low of $65.25 and a one year high of $92.64.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $1.50 EPS for the quarter, topping the Zacks’ consensus estimate of $1.34 by $0.16. The business had revenue of $12.06 billion for the quarter, compared to analyst estimates of $11.46 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 52.46%. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.22 earnings per share. Research analysts anticipate that Merck & Co., Inc. will post 5.31 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 7th. Stockholders of record on Monday, June 15th will be given a $0.61 dividend. This represents a $2.44 dividend on an annualized basis and a dividend yield of 2.97%. The ex-dividend date is Friday, June 12th. Merck & Co., Inc.’s dividend payout ratio is presently 47.01%.

In other news, Director Wendell P. Weeks sold 5,000 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $76.02, for a total value of $380,100.00. Following the sale, the director now owns 5,100 shares of the company’s stock, valued at $387,702. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.28% of the company’s stock.

A number of research analysts recently issued reports on MRK shares. Barclays lowered their target price on shares of Merck & Co., Inc. from $93.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 29th. SVB Leerink lowered their target price on shares of Merck & Co., Inc. from $98.00 to $95.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 29th. Mizuho reiterated a “buy” rating on shares of Merck & Co., Inc. in a research note on Wednesday, February 5th. UBS Group lowered their target price on shares of Merck & Co., Inc. from $96.00 to $92.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Finally, Guggenheim lowered their target price on shares of Merck & Co., Inc. from $101.00 to $93.00 and set a “buy” rating on the stock in a research note on Wednesday, April 29th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Merck & Co., Inc. currently has an average rating of “Buy” and an average price target of $94.21.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Beige Book

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.